Metzcar J, Guenter R, Wang Y, Baker K, Lines K
Endocr Oncol. 2025; 5(1):e240025.
PMID: 39949335
PMC: 11825163.
DOI: 10.1530/EO-24-0025.
Wan Z, Yuan M, Liu Z, Cai Y, He H, Hao K
AAPS J. 2025; 27(1):38.
PMID: 39900889
DOI: 10.1208/s12248-025-01024-x.
Niazi S
Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004421
PMC: 10675618.
DOI: 10.3390/ph16111556.
Zhang L, Liu M, Qin W, Shi D, Mao J, Li Z
Front Pharmacol. 2023; 14:1228641.
PMID: 37869748
PMC: 10587682.
DOI: 10.3389/fphar.2023.1228641.
Zhu J, Zhang Y, Zhao Y, Zhang J, Hao K, He H
Pharmaceutics. 2023; 15(9).
PMID: 37765243
PMC: 10535808.
DOI: 10.3390/pharmaceutics15092274.
Pharmacodynamic Model of the Dynamic Response of Biofilms to Antibacterial Treatments.
Roychowdhury S, Roth C
Biomedicines. 2023; 11(8).
PMID: 37626812
PMC: 10452719.
DOI: 10.3390/biomedicines11082316.
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
Ernest J, Goh J, Strydom N, Wang Q, Van Wijk R, Zhang N
Eur Respir J. 2023; 62(2).
PMID: 37321622
PMC: 10469274.
DOI: 10.1183/13993003.00165-2023.
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions.
Grant J, Hua F, Apgar J, Burke J, Marcantonio D
MAbs. 2023; 15(1):2192251.
PMID: 36951503
PMC: 10038042.
DOI: 10.1080/19420862.2023.2192251.
A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.
Yao X, Zhou J, Song L, Ren Y, Hu P, Liu D
CPT Pharmacometrics Syst Pharmacol. 2023; 12(4):487-499.
PMID: 36890732
PMC: 10088079.
DOI: 10.1002/psp4.12934.
Model Systems in Endometriosis Research: Translation, Translation, Translation!.
Groothuis P
Front Reprod Health. 2022; 3:809366.
PMID: 36304048
PMC: 9580766.
DOI: 10.3389/frph.2021.809366.
Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations.
Janssen A, Bennis F, Mathot R
Pharmaceutics. 2022; 14(9).
PMID: 36145562
PMC: 9502080.
DOI: 10.3390/pharmaceutics14091814.
Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development.
van Niel J, Bloms-Funke P, Caspani O, Cendros J, Garcia-Larrea L, Truini A
Int J Mol Sci. 2022; 23(15).
PMID: 35955432
PMC: 9368481.
DOI: 10.3390/ijms23158295.
Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing.
Yow H, Govindaraju K, Lim A, Abdul Rahim N
Front Pharmacol. 2022; 13:915355.
PMID: 35814236
PMC: 9260690.
DOI: 10.3389/fphar.2022.915355.
Growth-rate model predicts in vivo tumor response from in vitro data.
Diegmiller R, Salphati L, Alicke B, Wilson T, Stout T, Hafner M
CPT Pharmacometrics Syst Pharmacol. 2022; 11(9):1183-1193.
PMID: 35731938
PMC: 9469692.
DOI: 10.1002/psp4.12836.
Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.
Kesharwani P, Kumari K, Gururani R, Jain S, Sharma S
Curr Drug Metab. 2022; 23(9):678-692.
PMID: 35692131
DOI: 10.2174/1389200223666220609141459.
Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma.
Mao J, Li Q, Li P, Qin W, Chen B, Zhong M
Front Pharmacol. 2022; 13:817673.
PMID: 35355729
PMC: 8959905.
DOI: 10.3389/fphar.2022.817673.
Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs.
Wen H, Wang C, Li J, Jiao Z
Front Oncol. 2022; 11:814699.
PMID: 35083161
PMC: 8784755.
DOI: 10.3389/fonc.2021.814699.
Combination therapy for cerebral ischemia: do progesterone and noscapine provide better neuroprotection than either alone in the treatment?.
Kawadkar M, Mandloi A, Singh N, Mukharjee R, Dhote V
Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(2):167-185.
PMID: 34988596
DOI: 10.1007/s00210-021-02187-y.
Factors Affecting Time-Varying Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective.
Mao J, Qiu X, Qin W, Xu L, Zhang M, Zhong M
Pharm Res. 2021; 38(11):1873-1887.
PMID: 34750720
DOI: 10.1007/s11095-021-03114-9.
A quantitative systems pharmacology approach to predict the safe-equivalent dose of doxorubicin in patients with cardiovascular comorbidity.
Sang L, Yuan Y, Zhou Y, Zhou Z, Jiang M, Liu X
CPT Pharmacometrics Syst Pharmacol. 2021; 10(12):1512-1524.
PMID: 34596967
PMC: 8673998.
DOI: 10.1002/psp4.12719.